Galmed announces approval of ind application in china for aramchol for the treatment of nash & fibrosis in the global phase 3 armor registrational study

Tel aviv, israel, may 3, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the national medical products administration (nmpa) has granted approval for the investigational new drug (ind) application for galmed's phase 3 armor registrational study of aramchol for the treatment of nash & fibrosis.
GLMD Ratings Summary
GLMD Quant Ranking